The NCI designation also facilitates the formal establishment of research consortia, creating a network of collaborative institutions known as consortium cancer centers.
What is a Consortium Cancer Center?
NCI recognizes a Consortium Cancer Center when investigators from separate scientific institutions partner to contribute actively to the development and achievement of a shared cancer research agenda. These centers demonstrate a high level of scientific engagement and interaction, with each member institution adding strategic value to the research mission. The term Consortium Cancer Center is applied to an NCI-designated center with a non-designated partner.
Our Partnership With Princeton University
Rutgers Cancer Institute's NCI designation empowered the Comprehensive Cancer Center to develop a formally established research consortium with Princeton University. The close geographic proximity between the Universities enhances the interactions and collaborations within this unique consortium that brings together the largest public and private Universities in New Jersey dedicated to a common mission: to eradicate cancer.
Benefits of Our Consortium Partnership
Scientific Advances in Various Aspects of Cancer
As a result of the relationship, scientific advances in the areas of cancer metabolism, genomics, and metastasis have contributed to impactful scientific discoveries and clinical progress.
High-Profile Publications and Grants
Collaborative research between investigators at Rutgers and Princeton Universities has led to many high-profile publications and garnered millions of dollars in federal research grants.
To further promote research collaboration across the consortium, Rutgers Cancer Institute allocates funding annually for pilot awards to support cancer research projects co-led by investigators at Rutgers and Princeton Universities.
Shared Resource Core Facilities
Federal and operational funding is also invested in supporting and developing shared resource core facilities across the Rutgers and Princeton University campuses. These shared resource core facilities offer an array of highly specialized cancer research equipment and services, including expert training in research techniques.
Continued Training for Professionals in Cancer Care
Each year, Rutgers Cancer Institute members spanning both Rutgers and Princeton Universities host joint retreats, internship programs, and other collaborative initiatives that train the next generation of cancer research scientists and physicians.
Special Focus on Cancer Metabolism With Ludwig Cancer Research
Based at Princeton University, the Ludwig Princeton Branch is dedicated to the study of cancer metabolism. Combined with Ludwig’s leadership in cancer epigenetics and immunotherapy, advances in cancer metabolism generated at the Ludwig Princeton Branch will inform new strategies for cancer prevention and treatment. The clinical translation of Branch discoveries will be conducted in the tri-state area, including in partnership with RWJBarnabas Health and Rutgers Cancer Institute.
Shared Onsite Resources at Princeton University
Associate Director for Consortium Research
Yibin Kang, PhD, Warner-Lambert / Parke-Davis Professor of Molecular Biology - Princeton University
As Associate Director, Consortium Research, Dr. Kang works closely with leadership at Princeton University and Rutgers Cancer Institute to recruit new members into the established Research Programs, identify opportunities to help clinical and population researchers link their work to the basic research base, and promote multidisciplinary cancer-focused training and develop new training opportunities across the consortium. He participates in the advisory committees of consortium-based shared resources, with special emphasis on the Flow Cytometry/Cell Sorting and Genome Editing Shared Resources. Dr. Kang also represents Princeton University in the cancer institute’s strategic planning, overseeing an integrated planning and evaluation process that enables achievement of research goals, identifying future recruitment and shared resource needs, and ensuring tangible commitments to the cancer institute across both Rutgers and Princeton Universities.
Consortium Steering Committee
Yibin Kang, PhD - Associate Director, Consortium Research, Chair, Consortium Steering Committee, Warner-Lambert / Parke-Davis Professor of Molecular Biology
Adam C. Berger, MD, FACS - Chief, Melanoma and Soft Tissue Surgical Oncology; Associate Director for Shared Resources
Stephen K. Burley, MD, DPhil - Director, Center for Integrative Proteomics Research; Program Co-Leader: Cancer Pharmacology; University Professor, School of Arts and Sciences
Karla Ewalt, PhD, Associate Dean for Research
Shridar Ganesan, MD, PhD - Program Co-Leader: Clinical Investigations and Precision Therapeutics; Associate Professor of Medicine & Pharmacology, Robert Wood Johnson Medical School
Haejin In, MD, MPH, MBA, FACS, FSSO - Chief Diversity Officer; Associate Director for Diversity, Equity and Inclusion; Associate Professor of Health, Behavior and Policy, Rutgers School of Public Health
Anita Kinney, PhD - Associate Director, Population Science & Community Outreach at the Rutgers Cancer Institute; Director, Center for Cancer Health Equity, School of Public Health and Rutgers Cancer Institute; Director, ScreenNJ; Professor of Biostatistics and Epidemiology, School of Public Health
Edmund Lattime, PhD - Associate Director for Education and Training; Professor of Surgery and Biochemistry & Molecular Biology, Robert Wood Johnson Medical School
Michael Levine, PhD - Director, Lewis-Sigler Institute for Integrative Genomics; Professor of Molecular Biology
Joshua Rabinowitz, MD, PhD - Shared Resource Director: Metabolomics; Member of the Lewis-Sigler Institute for Integrative Genomics; Professor of Chemistry
Related Articles and Press
Rutgers Cancer Institute and Princeton University investigators aim to address treatment resistance in non-small cell lung cancer (NSCLC).